1. Home
  2. BTT vs IOVA Comparison

BTT vs IOVA Comparison

Compare BTT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Municipal 2030 Target Term Trust

BTT

BlackRock Municipal 2030 Target Term Trust

HOLD

Current Price

$22.90

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.42

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTT
IOVA
Founded
2012
2007
Country
United Kingdom
United States
Employees
N/A
975
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
BTT
IOVA
Price
$22.90
$3.42
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$9.00
AVG Volume (30 Days)
111.6K
13.7M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
2.95%
N/A
EPS Growth
N/A
14.84
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$47.74
Revenue Next Year
N/A
$40.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.05
$1.64
52 Week High
$23.24
$5.63

Technical Indicators

Market Signals
Indicator
BTT
IOVA
Relative Strength Index (RSI) 49.77 44.48
Support Level $22.27 $2.05
Resistance Level $23.03 $4.33
Average True Range (ATR) 0.16 0.30
MACD -0.00 -0.02
Stochastic Oscillator 40.32 22.44

Price Performance

Historical Comparison
BTT
IOVA

About BTT BlackRock Municipal 2030 Target Term Trust

Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: